Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03165942 · ClinicalTrials.gov registry record · Phase 1
Neuroendocrine Response to Oral Alcohol Administration
A Phase 1 study, sponsored by Yale University.
- Completed
- Registry status
- Phase 1
- Development phase
- 64
- Enrollment target
NCT03165942 is a Phase 1 study that has completed, run by Yale University. The registered enrollment target is 64 participants.
The verdict
NCT03165942, a Phase 1 study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 64 participants
- Enrollment target
Study Summary
This study proposes to examine both the peripheral and central nervous system responses when light social drinkers and binge/heavy social drinkers are exposed to oral ethanol. The findings will provide a greater understanding of the brain mechanisms (cerebral blood flow and functional connectivity) underlying the association between stress, cortisol release, heart rate variability, alcohol craving, and alcohol stimulant and sedative effects. This knowledge could be significant in developing new therapies for the treatment of alcoholism.
Interventions
- DRUG Ethanol
- OTHER Alcoholic Beverage
- OTHER Non-Alcoholic Beverage
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2016-09-08 |
| Est. Completion | 2018-06-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03165942
The ClinicalTrials.gov registry entry for NCT03165942 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Ethanol is the first listed.
NCT03165942 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03165942 about?
NCT03165942 is a clinical study titled "Neuroendocrine Response to Oral Alcohol Administration". This study proposes to examine both the peripheral and central nervous system responses when light social drinkers and binge/heavy social drinkers are exposed to oral ethanol. The findings will provide a greater understanding of the brain mechanisms (cerebral blood flow and functional connectivity) ...
What is the current status of trial NCT03165942?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 64 participants. The study started on 2016-09-08. Estimated completion is 2018-06-30.
What interventions are being tested in trial NCT03165942?
The interventions under investigation include: Ethanol (DRUG), Alcoholic Beverage (OTHER), Non-Alcoholic Beverage (OTHER).
Who is sponsoring clinical trial NCT03165942?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.